These findings are consistent with the established biology of thyroid tumors: BRAF mutations are strongly associated with classic PTC, while FV-PTC is more frequently driven by RAS mutations, and medullary carcinoma by RET alterations [37,38,39]. The gene discussed is RET; the disease is thyroid tumor.